Inhaled corticosteroid

In a 2-year double-blind study in 103 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV 1 85%-88% predicted), treatment with mometasone furoate dry powder inhaler 200 mcg twice daily resulted in significant reductions in lumbar spine (LS) BMD at the end of the treatment period compared to placebo. The mean change from Baseline to Endpoint in the lumbar spine BMD was - (-%) for the mometasone furoate dry powder inhaler group compared to (%) for the placebo group. In another 2-year double-blind study in 87 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV 1 82%-83% predicted), treatment with mometasone furoate dry powder inhaler 400 mcg twice daily demonstrated no statistically significant changes in lumbar spine BMD at the end of the treatment period compared to placebo. The mean change from Baseline to Endpoint in the lumbar spine BMD was - (-%) for the mometasone furoate group compared to - (-%) for the placebo group.

The recruited patients had a median (inter-quartile ranges) FENO level of 19 ppb (12-30 ppb). Patients with chronic cough had a significantly higher median FENO level than those with subacute cough ( vs 16 ppb; Z=-, P=). A FENO level ≥25 ppb was recorded in 15 (%) patients with subacute cough, as compared with 20 (%) in patients with chronic cough (χ(2)=, P=). With a FENO ≥25 ppb as the critical value to justify ICS treatment, 15 patients with subacute cough received ICS and 14 (%) of them showed obvious relief of cough after 2 weeks of therapy, a response rate similar to that of % (17/20) in patients with chronic cough receiving the treatment (χ(2)=, P=). In patients with subacute cough, those with cough variant asthma (CVA) or eosinophilic bronchitis (EB) had a significantly higher median FENO level than those with postinfectious cough [(16 (11-31) ppb vs 11 (8-19) ppb, P<]. In the etiological analysis, CVA or EB was identified in 23 (%) of the patients with subacute cough, as compared 21 (%) in patients with chronic cough (χ(2)=, P=).

Some parents worry that children who use inhaled corticosteroids may not grow as tall as other children. A very small difference in height and growth was found in children who were using inhaled corticosteroids compared to children not using them. 3 And one study showed a very small difference in height [about in. ( cm) ] in adults who used inhaled corticosteroids as children compared to adults who did not use inhaled corticosteroids. 4 But the use of inhaled corticosteroids has important health benefits for children who have asthma. If you are worried about the effects of asthma medicines on your child, talk with your doctor.

Inhaled corticosteroid

inhaled corticosteroid

Media:

inhaled corticosteroidinhaled corticosteroidinhaled corticosteroidinhaled corticosteroidinhaled corticosteroid